The Hansa Medical candidate drug IdeS has enabled

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 18, 2014 at 2:15 AM

The Hansa Medical candidate drug IdeS has enabled successful kidney transplantation

A successful kidney transplantation of an HLA sensitized patient has been accomplished following desensitization with the candidate drug IdeS at Uppsala University Hospital. The patient is enrolled in the ongoing Phase II study sponsored by Hansa Medical with the primary objective to study IdeS’ capacity to reduce levels of anti-HLA antibodies in sensitized patients. HLA sensitized patients rarely become transplanted due to the immediate risk of transplant rejection caused by donor specific anti-HLA antibodies. However, following treatment with IdeS the now transplanted patient became eligible for deceased donor transplantation after treatment with IdeS. The cross match test, determining if the patient was compatible with the deceased donor, showed that the donor specific antibodies had been completely inactivated by the IdeS -treatment making the cross match negative. The patient was then successfully transplanted and the transplanted kidney is now perfectly functional. “We have demonstrated, for the first time, that IdeS can enable transplantation for patients burdened by anti-HLA antibodies as the primary obstacle to transplantation. I am very happy that we by treatment with IdeS, have managed to help this patient to become transplanted,” comments Emanuel Björne, CEO Hansa Medical AB (publ). Thousands of sensitized patients around the world live in a hopeless wait, hindered from transplantation due to high levels of anti-HLA antibodies. These patients face long-term dialysis, associated with significantly shortened life expectancy and reduced quality of life. The goal of Hansa Medical is that all these patients shall be transplanted through treatment with IdeS. “We have purposefully brought our unique IdeS-concept from discovery, through phases of research and development into effective and safe treatment of a patient. This brings hope to patients in need and is a major success for my dedicated colleagues here at Hansa Medical and at Uppsala University Hospital as well as for our long term committed owners whose investments made this possible,” concludes Emanuel Björne, CEO Hansa Medical AB (publ). More on IdeS The candidate drug IdeS is developed as a fast, effective and safe method to deactivate anti-HLA antibodies in sensitized patients prior to kidney transplantation. During 2013, a successful Phase I-study on 29 healthy subjects was performed, demonstrating IdeS as efficacious and well tolerated with a favourable safety profile. The purpose of the ongoing Phase II-study is to explore IdeS’ safety and efficacy on anti-HLA antibodies in sensitized patients awaiting kidney transplantation. The objective is to generate significant clinical data in order to enable a pivotal phase III trial. In total, approximately 20 patients will be enrolled in two separate phase II studies planned to last until the second quarter of 2015. For further information, please contact: Hansa Medical AB Emanuel Björne, CEO Hansa Medical AB (publ) Mobile: 46 707 17 54 77 E-mail: emanuel.bjorne@hansamedical.com www.hansamedical.com Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser. The information in this press release is such information that Hansa Medical AB (publ) is obliged to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on August 18, 2014 at 08:00 CET.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Life Time's Q3 2026 Results Highlight Solid Growth

Life Time Rolls On With Strong Q3 Performance Sometimes the market hands you pure gold, and that's what Life Time (NYSE: LTH) has right now. They didn't just have a decent quarter; they outright nailed it with a $893.5 million total revenue haul—a hefty 14.2% rise from the prior year. What's driving this ship? Solid growth in membership dues and dynamic personal...

CPSC's Battle Against Dangerous Imports Intensifies

Feldman Sounds Alarm at Bangkok Conference Imagine the chaos if safety took a back seat in our daily lives. Well, that's exactly what's at stake with the influx of dangerous consumer products sailing into our markets. Acting Chairman of the U.S. Consumer Product Safety Commission (CPSC), Peter A. Feldman, gave a no-holds-barred speech on this matter at the INTERPOL...

Huron Consulting Joins S&P SmallCap 600 Lineup Soon

Shuffling the Deck: Huron Consulting Steps In Just when you thought the index shuffle was settled, along comes an eleventh-hour change. Huron Consulting Group is being welcomed with open arms into the S&P SmallCap 600, booting Supernus Pharmaceuticals to the side. Mark November 3 on your calendars—final scorecards before the trading bell could surprise us all. The S&P...

Sol Taps Silberman: Bold New Era for Marketing Shift

Bringing Media Savvy to AI Strategy Dan Silberman, the seasoned media executive from A+E Global Media, just jumped ship to helm marketing and communications at Sol, a firm peddling its ware in AI-enabled business transformation. Maybe you're scratching your head, wondering why the heck it matters. Well, as I see it, this ain't just another name change on a corporate...

2026 Environmental Leadership Awards Unveiled by SP

Celebrating Green Pioneers: SP's Vision in Action Right out of Indianapolis, there's a buzz around the Suppliers Partnership for the Environment's big reveal: the 2026 Environmental Leadership Award recipients. These aren't just plaques to hang on a wall; these awards shout out significant strides in automotive sustainability. Recognized players like Visscher-Caravelle,...

Solink Secures $100M: NYSE Sees Tech and Sports Moves

Folks, it’s a busy day on Wall Street, with Solink leading the charge by landing over a cool $100 million in fresh funding. Let's break this down because when startups pocket nine-digit figures, it's time to pay attention. Solink's Leap Forward Now, what’s Solink doing with all that cash? They're not scrambling for coffee money, that's for sure. Instead, this funding...

Palmdale Propane Expands with Affordable Gas Buy

Propane Power Play in Florida's Market Here's a little tune you don't hear every day: two local businesses tangoing to the beat of expansion without making a public peep about the price. Palmdale Propane, a powerhouse under the Palmdale Oil umbrella, just snapped up Affordable Gas, a local player from Belle Glade, Florida. This acquisition strengthens its grip on the...

Keeping Halloween Safe and Fun with AHN Tips

Trick or Treat the Safe Way Ah, Halloween. A time when you don't just get to pretend to be someone else; you get to pile on the candy like it's a second job. But hold up! Before your pint-sized Dracula sprints into the foggy night, heed some wisdom from the folks at Allegheny Health Network. They aren't just offering another bowl of sugar-coated advice; they've got...

Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...